July 25, 2017 10:11 PM ET

Biotechnology

Company Overview of Conatus Pharmaceuticals Inc.

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

16745 West Bernardo Drive

Suite 200

San Diego, CA 92127

United States

Founded in 2005

25 Employees

Phone:

858-376-2600

Key Executives for Conatus Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer, President, Acting Principal Financial Officer and Director
Age: 65
Total Annual Compensation: $503.8K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Age: 59
Total Annual Compensation: $386.7K
Executive Vice President of Clinical Development
Age: 62
Total Annual Compensation: $389.2K
Compensation as of Fiscal Year 2016.

Conatus Pharmaceuticals Inc. Key Developments

FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

Conatus Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Conatus drug candidate IDN-7314 for the treatment of primary sclerosing cholangitis, a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. The FDA's Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions. IDN-7314 is an orally active pan-caspase protease inhibitor designed to reduce the ctivity of enzymes that mediate inflammation and cell death (or apoptosis), which has demonstrated reduction of relevant biomarkers in two preclinical models of PSC. One nonclinical model, the Mdr2-/- (knockout) mouse model, is considered the current benchmark nonclinical model of PSC. A new preclinical model, second mitochondria-derived activator of caspases (SMAC)-mimetic induced PSC in mice, has recently been reported that reproduces much of the phenotype of human PSC. IDN-7314 significantly improved biochemical indices of hepatic and biliary damage in these murine models of PSC, and these results suggest the involvement of caspases in the progression of PSC.

Conatus Pharmaceuticals Seeks Acquisitions

Conatus Pharmaceuticals Inc. (NasdaqGM:CNAT) recently disclosed plans for a public offering of its common stock. It plans to use a portion of the net proceeds from the offering to repurchase and retire nearly 2.2 million Conatus shares now owned by Advent Private Equity at a price per share equal to the offering price after first paying underwriter discounts and other offering expenses. Any remaining funds will fund potential drug pipeline purchases as well as for working capital and other general corporate purposes, Conatus said.

Conatus Pharmaceuticals Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2017

Conatus Pharmaceuticals Inc. reported unaudited earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported revenues of $7.0 million compared with $0.0 million for the first quarter of 2016. The net loss was $3.6 million compared with $7.3 million for the first quarter of 2016. Loss from operations was $3,690,660 against $7,274,589 a year ago. Net loss per share, basic and diluted was $0.14 against $0.35 a year ago.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 19, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Conatus Pharmaceuticals Inc., please visit www.conatuspharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.